肿瘤资讯 学术大使 2022-05-03 19:00
一年一度2022美国临床肿瘤学会（ASCO）年会即将再次来临，此次会议已是58届，定于美国当地时间2022年06月03-07日举行。ASCO官网日前正式公布了本次会议的详细日程。作为肿瘤界首屈一指的交流盛会，每年的ASCO年会都会带来最前沿的肿瘤研究内容。让我们先看看今年入选ASCO乳腺肿瘤的研究有哪些吧！具体研究摘要详情，请关注【肿瘤资讯】后续追踪。
全体大会（Plenary Session）
在HER2低表达不可切除和/或转移性乳腺癌(mBC)患者中比较T-DXd与医生选择的治疗(TPC)：一项随机、III期研究DESTINY-Breast04的结果
题目：Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
汇报人：Shanu Modi, MD
汇报时间：6月6日，上午3:17（以下均为北京时间）
摘要号：LBA3
口头报告大会（Oral Abstract Session）
专场：转移性乳腺癌
在HER2阳性不可切除和/或转移性乳腺癌(mBC)患者中比较T-DXd与T-DM1：随机、III期研究DESTINY-Breast03的安全性随访
题目：Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
汇报人：Erika P. Hamilton, MD
汇报时间：6月5日，上午2:15
摘要号：1000
TROPiCS-02的主要结果：一项在HR +/HER2-晚期乳腺癌患者中比较戈沙妥珠单抗(SG)与医生选择的治疗(TPC)的随机III期研究
题目：Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
汇报人：Hope S. Rugo, FASCO, MD
汇报时间：6月5日，上午2:27
摘要号：LBA1001
靶向HER3的抗体偶联药物(ADC)patritumab deruxtecan治疗表达HER3转移性乳腺癌(MBC)患者的I/II期研究结果
题目：Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
汇报人：Ian E. Krop, PhD, MD
汇报时间：6月5日，上午2:39
摘要号：1002
ER +/HER2-晚期乳腺癌(ABC)女性患者接受哌柏西利+来曲唑对比安慰剂 + 来曲唑(PBO + LET) 一线治疗的总生存期(OS)：PALOMA-2分析
题目：Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
汇报人：Richard S. Finn, MD
汇报时间：6月5日，上午3:15
摘要号：LBA1003
MAINTAIN试验：在不可切除的HR +、HER2阴性转移性乳腺癌(MBC)中，接受CDK4/6i联合内分泌治疗后进展的患者，使用氟维司群或依西美坦联合或不联合ribociclib的随机、II期试验
题目：A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
汇报人：Kevin Kalinsky, MD, MS
汇报时间：6月5日，上午3:27
摘要号：LBA1004
AI治疗后复发或进展的转移性雌激素受体阳性乳腺癌患者，接受氟维司群 + capivasertib与氟维司群 + 安慰剂的比较(FAKTION)：总生存期和通过生物标志物分析的无进展生存期数据更新
题目：Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.
汇报人：Robert Hugh Jones, PhD
汇报时间：6月5日，上午3:39
摘要号：1005
Alpelisib+氟维司群用于HR+/HER2-晚期乳腺癌(ABC)患者：通过新一代测序(NGS)在SOLAR-1研究中进行的生物标志物分析
题目：Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.
汇报人：Dejan Juric, MD
汇报时间：6月5日，上午3:51
摘要号：1006
NRG-BR002：一项采用或不采用立体定向放射治疗(SBRT)和/或手术切除的标准全身治疗新发寡转移性乳腺癌的IIR/III期试验(NCT02364557)
题目：NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).
汇报人：Steven J. Chmura, PhD, MD
汇报时间：6月5日，上午4:27
摘要号：1007
2000-2017年间，筛查、早期治疗和转移治疗对降低美国不同分子分型女性乳腺癌死亡率的贡献
题目：Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017.
汇报人：Jennifer Lee Caswell-Jin, BA, MD
汇报时间：6月5日，上午4:39
摘要号：1008
专场：乳腺癌-局部/区域/辅助
LUMINA：T1N0的luminalA型乳腺癌保乳手术(BCS)后省略放疗(RT)的前瞻性试验
题目：LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).
汇报人：Timothy Joseph Whelan, FASCO
汇报时间：6月7日，下午10:45
摘要号：LBA501
通过7基因预测的DCIS生物标记进行分层，评估辅助内分泌治疗对接受保乳手术联合或不联合放疗的患者的益处
题目：Assessing the benefit of adjuvant endocrine therapy in patients following breast-conserving surgery with or without radiation stratified by a 7-gene predictive DCIS biosignature.
汇报人：Pat W. Whitworth, MD
汇报时间：6月7日，下午10:57
摘要号：502
早期TNBC新辅助帕博利珠单抗+化疗与安慰剂+化疗后按残存肿瘤负荷的无事件生存期：KEYNOTE-522的探索性分析
题目：Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.
汇报人：Lajos Pusztai, D.Phil, MD
汇报时间：6月7日，下午11:33
摘要号：503
I-SPY2试验中，按分子亚型列出的HR+/HER2-乳腺癌的病理学完全缓解(pCR)率
题目：Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
汇报人：Laura Ann Huppert, MD
汇报时间：6月7日，下午11:45
摘要号：504
雌激素受体阳性(ER +)癌症中与预后相关的内分泌活性(SET2,3)测量和剂量密集(DD)化疗获益预测：CALGB 9741(Alliance)
题目：Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer: CALGB 9741 (Alliance).
汇报人：Otto Metzger, MD
汇报时间：6月7日，下午11:57
摘要号：505
辅助内分泌治疗±化疗治疗≥70岁ER + HER2-乳腺癌和高基因组分级指数女性的III期随机临床试验的最终结果：Unicancer ASTER 70s试验
题目：Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial.
汇报人：Etienne Brain, MD, PhD
汇报时间：6月8日，上午00:33
摘要号：500
在化疗后仍未绝经或恢复月经的激素敏感性乳腺癌年轻女性中，在他莫昔芬基础上加用卵巢功能抑制：随机试验ASTRRA的8年随访
题目：Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial.
大会发言：Soo Yeon Baek, MD
汇报时间：6月8日，上午00:45
摘要号：506
地舒单抗辅助治疗乳腺癌的长期结局：随机、双盲、安慰剂对照ABCSG-18试验中，3425例患者的骨折复位和生存结果
题目：Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial
汇报人：Michael Gnant, FACS, MD
汇报时间：6月8日，上午00:57
摘要号：507
高危亚组乳腺癌辅助内分泌治疗的既往早期治疗效果：BIG 1-98、SOFT和TEXT的再分析
题目：Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT.
汇报人：Meredith M. Regan, ScD, FASCO
汇报时间：6月8日，上午1:09
摘要号：508
临床科学论坛
（Clinical Science Symposium）
专场：基因组学用于指导HR+/HER2-乳腺癌的治疗
plasmaMATCH研究中，ESR1 F404突变与氟维司群获得性耐药
题目：ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study.
汇报人：Belinda Kingston, MD
汇报时间：6月7日，上午5:30
摘要号：1009
RB1的等位基因突变导致CDK4/6抑制剂治疗转移性乳腺癌的耐药性
题目：Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.
汇报人：Anton Mikhailovich Safonov, MD
汇报时间：6月7日，上午5:42
摘要号：1010
真实世界数据(RWD)评估血浆游离DNA(cfDNA)在识别晚期乳腺癌(aBC)早期治疗耐药中的实用性
题目：Use of real-world data (RWD) to assess the utility of cell-free circulating tumor DNA (cfDNA) in identifying resistance to early treatment in advanced breast cancer (aBC).
汇报人：Seth Andrew Wander, MD, PhD
汇报时间：6月7日，上午6:06
摘要号：1011
在BioItaLEE试验中，HR +/HER2-晚期乳腺癌(ABC)患者接受ribociclib(RIB)和来曲唑(LET)一线治疗后的循环肿瘤DNA(ctDNA)和血清胸苷激酶1活性(TKa)的匹配动力学
题目：Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor 2–negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial.
汇报人：Grazia Arpino
汇报时间：6月7日，上午6:18
摘要号：1012
